Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idarubicin and Azacitidine in High Risk MDS
NCT01305135Phase 2Completed
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Dec 2010
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of idarubicin in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by Groupe Français des Myélodysplasies. Started Dec 2010; status: completed.
02
Drugs
idarubicin
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT01305135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01305135.